Research Recommendations Following the Discovery of Pain Sensitizing IgG Autoantibodies in Fibromyalgia Syndrome.
Autoantibodies
Fibromyalgia
Research Priorities
Journal
Pain medicine (Malden, Mass.)
ISSN: 1526-4637
Titre abrégé: Pain Med
Pays: England
ID NLM: 100894201
Informations de publication
Date de publication:
30 05 2022
30 05 2022
Historique:
received:
02
09
2021
revised:
15
11
2021
accepted:
16
11
2021
pubmed:
2
12
2021
medline:
3
6
2022
entrez:
1
12
2021
Statut:
ppublish
Résumé
Fibromyalgia syndrome (FMS) is the most common chronic widespread pain condition in rheumatology. Until recently, no clear pathophysiological mechanism for fibromyalgia had been established, resulting in management challenges. Recent research has indicated that serum immunoglobulin Gs (IgGs) may play a role in FMS. We undertook a research prioritisation exercise to identify the most pertinent research approaches that may lead to clinically implementable outputs. Research priority setting was conducted in five phases: situation analysis; design; expert group consultation; interim recommendations; consultation and revision. A dialogue model was used, and an international multi-stakeholder expert group was invited. Clinical, patient, industry, funder, and scientific expertise was represented throughout. Recommendation-consensus was determined via a voluntary closed eSurvey. Reporting guideline for priority setting of health research were employed to support implementation and maximise impact. Arising from the expert group consultation (n = 29 participants), 39 interim recommendations were defined. A response rate of 81.5% was achieved in the consensus survey. Six recommendations were identified as high priority- and 15 as medium level priority. The recommendations range from aspects of fibromyalgia features that should be considered in future autoantibody research, to specific immunological investigations, suggestions for trial design in FMS, and therapeutic interventions that should be assessed in trials. By applying the principles of strategic priority setting we directed research towards that which is implementable, thereby expediating the benefit to the FMS patient population. These recommendations are intended for patients, international professionals and grant-giving bodies concerned with research into causes and management of patients with fibromyalgia syndrome.
Sections du résumé
BACKGROUND
Fibromyalgia syndrome (FMS) is the most common chronic widespread pain condition in rheumatology. Until recently, no clear pathophysiological mechanism for fibromyalgia had been established, resulting in management challenges. Recent research has indicated that serum immunoglobulin Gs (IgGs) may play a role in FMS. We undertook a research prioritisation exercise to identify the most pertinent research approaches that may lead to clinically implementable outputs.
METHODS
Research priority setting was conducted in five phases: situation analysis; design; expert group consultation; interim recommendations; consultation and revision. A dialogue model was used, and an international multi-stakeholder expert group was invited. Clinical, patient, industry, funder, and scientific expertise was represented throughout. Recommendation-consensus was determined via a voluntary closed eSurvey. Reporting guideline for priority setting of health research were employed to support implementation and maximise impact.
RESULTS
Arising from the expert group consultation (n = 29 participants), 39 interim recommendations were defined. A response rate of 81.5% was achieved in the consensus survey. Six recommendations were identified as high priority- and 15 as medium level priority. The recommendations range from aspects of fibromyalgia features that should be considered in future autoantibody research, to specific immunological investigations, suggestions for trial design in FMS, and therapeutic interventions that should be assessed in trials.
CONCLUSIONS
By applying the principles of strategic priority setting we directed research towards that which is implementable, thereby expediating the benefit to the FMS patient population. These recommendations are intended for patients, international professionals and grant-giving bodies concerned with research into causes and management of patients with fibromyalgia syndrome.
Identifiants
pubmed: 34850195
pii: 6443164
doi: 10.1093/pm/pnab338
pmc: PMC9157149
doi:
Substances chimiques
Autoantibodies
0
Immunoglobulin G
0
Banques de données
figshare
['10.6084/m9.figshare.12602186']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1084-1094Subventions
Organisme : Versus Arthritis
ID : 21544
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S003428/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 104079/Z/14/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Academy of Pain Medicine.
Références
Rheumatology (Oxford). 2018 Nov 1;57(11):1982-1990
pubmed: 30053166
J Clin Apher. 2018 Dec;33(6):661-665
pubmed: 30387202
J Pain. 2016 Sep;17(9 Suppl):T93-T107
pubmed: 27586833
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):13067-13076
pubmed: 31182576
Scand J Rheumatol. 1997;26(4):308-13
pubmed: 9310112
Neuron. 2018 Feb 21;97(4):806-822.e10
pubmed: 29429934
J Rheumatol. 2009 Apr;36(4):671-8
pubmed: 19342721
Anesthesiology. 2013 Dec;119(6):1434-43
pubmed: 24343289
J Med Internet Res. 2004 Sep 29;6(3):e34
pubmed: 15471760
Ann Intern Med. 2020 Mar 3;172(5):ITC33-ITC48
pubmed: 32120395
Pain Med. 2002 Jun;3(2):119-27
pubmed: 15102158
Pain Res Manag. 2013 Jan-Feb;18(1):19-24
pubmed: 23457682
Ann Neurol. 2018 Mar;83(3):553-561
pubmed: 29406578
Rheum Dis Clin North Am. 2009 May;35(2):329-37
pubmed: 19647146
Ann Neurol. 2019 Oct;86(4):504-516
pubmed: 31376174
Ann Rheum Dis. 2016 Apr;75(4):730-8
pubmed: 26613766
J Clin Apher. 2016 Jun;31(3):149-62
pubmed: 27322218
Ann Neurol. 2014 Feb;75(2):196-208
pubmed: 24243538
Curr Opin Anaesthesiol. 2011 Oct;24(5):532-9
pubmed: 21799404
Pain. 2019 Jan;160(1):28-37
pubmed: 30586068
Ann Rheum Dis. 2017 Feb;76(2):318-328
pubmed: 27377815
Rheumatology (Oxford). 2008 Feb;47(2):208-11
pubmed: 18208823
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 34196305
Curr Med Res Opin. 2006 Oct;22(10):1911-20
pubmed: 17022849
Pain. 2010 Aug;150(2):250-256
pubmed: 20488620
Semin Arthritis Rheum. 2016 Dec;46(3):319-329
pubmed: 27916278
Scand J Pain. 2020 Oct 25;20(4):707-716
pubmed: 32841169
Rheumatology (Oxford). 2010 May;49(5):924-8
pubmed: 20100795
J Pain. 2017 Jul;18(7):835-843
pubmed: 28279705
BMC Med Res Methodol. 2019 Dec 28;19(1):243
pubmed: 31883517
Pain Med. 2014 Jul;15(7):1072-82
pubmed: 24422915
Anesthesiology. 2015 May;122(5):1103-11
pubmed: 25768860
Evol Appl. 2008 Feb;1(1):28-48
pubmed: 25567489
J Rheumatol. 2009 Jan;36(1):58-62
pubmed: 19132794
Arthritis Care Res (Hoboken). 2021 May;73(5):617-625
pubmed: 32248629
Arthritis Rheumatol. 2015 May;67(5):1386-94
pubmed: 25772388
Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 105(3):35-42
pubmed: 28229811